

ENANTA Pharmaceuticals, Inc.

500 Arsenal Street
Watertown, Massachusetts
02472

Tel: 617.607.0800
Fax: 617.607.0530
www.enanta.com

FOR IMMEDIATE RELEASE

CONTACT:

Susan Burke, Account Executive
Ronald Trahan Associates, Inc.
508-647-9782, ext. 20



**Enanta Pharmaceuticals appoints Ramesh Ratan
as Senior Vice President, Finance and Administration,
and Chief Financial Officer**

CAMBRIDGE, Mass., Aug. 9, 2001 -- Enanta Pharmaceuticals Inc., an emerging biopharmaceutical company, announced today the appointment of Ramesh Ratan as Senior Vice President of Finance and Administration and Chief Financial Officer, effective immediately.

Prior to joining Enanta Pharmaceuticals, Ramesh Ratan was Executive Vice President of Corporate Development and Chief Financial Officer at Equinox Solutions, Inc., since 1997. From 1995-1997, Mr. Ratan held the position of Executive Vice President of Business Development and Chief Financial Officer at American Superconductor Corporation. Prior to his position at American Superconductor Corporation, Mr. Ratan was Senior Vice President of Administration and Chief Financial Officer at Repligen Corporation from 1986 - 1994. His experience includes ten years with Bristol-Myers in Financial Planning and Analysis. Mr. Ratan earned a master's degree in industrial engineering at Syracuse University, after receiving his bachelor's degree in electrical engineering in India.

"Ramesh is a seasoned professional with a rare perspective on business development, as he has been an executive with Fortune-500 companies as well as with private and public emerging companies over the past 25 years. We are thrilled that he is joining our management team as we continue to build Enanta Pharmaceuticals into a successful drug discovery and drug development operation," said Dr. Spiros Jamas, Enanta's President and Chief Executive Officer.

Enanta Pharmaceuticals, founded in 1998, has raised \$25 million to date in private financing. Investors include: Oxford Bioscience Partners (lead investor), TVM - Techno Venture Management, Advent International Corporation, Lancet Capital and others.

Headquartered in Cambridge, Mass., Enanta Pharmaceuticals is creating its patented Morphed Chemical Entity (MCE™) libraries by transforming existing drugs, natural products and peptides into novel small-molecule drugs. The Company's initial focus is on MCEs derived from existing drugs that address significant unmet medical needs: (a)

new generation macrolide antibiotics to overcome bacterial resistance; and (b) anti-inflammatory drugs for a variety of indications, including asthma, psoriasis and inflammatory bowel diseases. Enanta is also using its proprietary Peptide Morphing™ capability to create improved antiviral drugs for HCV, HIV and HPV.

#####